The team’s entry point was a subtle mutation in histone H3, one of the core protein spools around which DNA is wound. They changed lysine 37, an amino acid predicted to make direct contact with the DNA backbone, into an alanine, creating the H3K37A mutant. The idea was straightforward: if this residue helps grip DNA, removing it should loosen the wrap. That is precisely what happened, but the downstream effects were anything but subtle. Cells carrying H3K37A began degrading their histones, a hallmark of chromatin instability, and their TORC1 kinase went into overdrive. Hyperactive TORC1 is normally a sign of a cell awash in nutrients; here it appeared without any change in the food supply, driven instead by a single altered amino acid in the genome’s packaging material.

To understand whether this TORC1 hyperactivation was merely a side effect or something with real consequences, the researchers threw a pharmacological wrench into the pathway. When they inhibited TORC1 in H3K37A cells, the cells died. This was the study’s first surprise, because TORC1 inhibition is usually survivable, if uncomfortable, for yeast. The toxicity was not a general property of chromatin instability, either. The team compared H3K37A to cells carrying wild-type histone H3 in which chromatin stability had been undermined by other means. Those cells also lost histones and also showed hyperactivated TORC1, yet they tolerated TORC1 inhibition just fine. Something about the H3K37A mutation specifically, rather than loose chromatin per se, primed cells for catastrophe when the nutrient-sensing pathway was throttled back.

The genetic interactions sharpened that conclusion. When the researchers combined H3K37A with mutations that destabilize chromatin in an otherwise wild-type histone context, the defects did not simply add up; they compounded. Histone loss grew worse, TORC1 activity climbed higher, and lethality during TORC1 inhibition became more severe. This synergy suggests that H3K37A and general chromatin instability damage overlapping but distinct aspects of genome packaging, and that the cell can absorb a certain amount of damage from either source alone. Pushed from both directions at once, the buffering capacity collapses. The result is a dose-response relationship between chromatin integrity and TORC1 control that had not been appreciated before, positioning histone-DNA contacts as an upstream restraint on one of the cell’s most consequential signaling pathways.

Why would a wobbly nucleosome care about a nutrient kinase? The answer, according to transcriptome profiling, lies in the mitochondria. The gene expression analysis revealed that H3K37A cells misregulate mitochondrial retrograde signaling, a stress-response program through which dysfunctional mitochondria inform the nucleus and trigger compensatory metabolic rewiring. In yeast, this pathway is classically activated when respiratory function falters, allowing cells to reconfigure carbon metabolism and survive on fermentation. In the mutant, this program was already deregulated at baseline, and inhibiting TORC1 made the derangement dramatically worse. The combination of a strained retrograde response and a suppressed growth pathway proved lethal, indicating that the two systems normally cooperate to keep mitochondrial stress manageable during metabolic adaptation.

The mechanistic thread connecting chromatin to mitochondrial function turned out to be protein import. The researchers found that H3K37A cells were defective in importing at least one oxidative phosphorylation, or OXPHOS, subunit into the mitochondria. OXPHOS complexes are assembled from components made in the cytosol and threaded through mitochondrial membrane transport machinery; a bottleneck at this step starves the respiratory chain of parts and undermines energy production. Defective import of an OXPHOS subunit provides a concrete, testable link between the nuclear defect and the mitochondrial phenotype, explaining how a histone mutation expressed in the nucleus can compromise the electron transport chain embedded in the inner mitochondrial membrane.

Two rescue experiments cemented the causal chain. First, when the team inactivated the retrograde pathway itself, the toxicity of TORC1 inhibition in H3K37A cells was prevented. This may seem paradoxical, since the retrograde response is usually framed as protective, but a misfired or incomplete retrograde program can apparently be worse than none at all, pushing cells into a metabolic configuration incompatible with reduced TORC1 activity. Second, neutralizing reactive oxygen species, the chemically reactive byproducts of mitochondrial electron leakage that accumulate when respiration goes awry, also blocked the lethality. Together, these results sketch a coherent pathway: chromatin instability deregulates retrograde signaling, retrograde dysfunction impairs mitochondrial protein import and respiratory capacity, ROS accumulate, and the cell crosses a viability threshold when TORC1 is simultaneously inhibited.

The conceptual payoff is the demonstration of bidirectional communication between chromatin and TORC1. The canonical view has TORC1 sitting at the top of a signaling hierarchy, phosphorylating downstream effectors that include chromatin-modifying enzymes and transcriptional regulators, thereby imposing nutrient-dependent patterns of gene expression. The new data invert part of that picture. Chromatin stability, embodied in a single histone residue that touches DNA, acts as an input that constrains TORC1 output. Lose that constraint and TORC1 hyperactivates, independent of nutrient status. This reframes chromatin not merely as a passive target of metabolic signaling but as an active participant in metabolic homeostasis, with histone-DNA contacts serving as a structural sensor whose integrity feeds back into growth control.

The study also assigns a previously unknown job to histone H3 lysine 37. Beyond its structural role in the nucleosome, the residue appears to have an additional functionality that protects mitochondrial regulation during metabolic stress adaptation. That kind of dual assignment is becoming a theme in chromatin biology, where histone residues are increasingly recognized as nodes connecting genome architecture to cellular physiology. It also raises evolutionary questions about why a DNA-contacting residue would be conserved partly for its role in mitochondrial governance, and whether analogous histone mutations in other organisms, including human disease variants, produce comparable metabolic vulnerabilities.

For the broader research community, the work opens several practical avenues. Cells with compromised chromatin may be silently hyperactivating TORC1, confounding experiments that interpret TORC1 activity purely as a readout of nutrient availability. Conversely, therapies that inhibit TOR signaling, a strategy under active investigation in cancer and aging research, could carry unappreciated risks for cells with chromatin instability, a common feature of tumors. And the mitochondria-centered toxicity mechanism suggests that antioxidants or interventions targeting retrograde signaling might mitigate such risks in susceptible contexts. What began as a question about a single lysine in a histone tail region has ended as a demonstration that the genome’s packaging material helps guard the cell’s energy supply, and that when the packaging fails, the growth-control machinery and the mitochondria fail with it.

Subject of Research: How chromatin stability regulates TORC1 signaling and mitochondrial homeostasis in yeast

Article Title: Chromatin stability safeguards mitochondrial homeostasis and restrains TORC1 signaling

Article References: Sigamani, V., Yousuf, M., Johnson, D. L., Strahl, B. D., & Laribee, R. N. (2026). Chromatin stability safeguards mitochondrial homeostasis and restrains TORC1 signaling. PLOS Genetics, 22(10), e1012330. https://doi.org/10.1371/journal.pgen.1012330

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012330

Keywords: chromatin, TORC1, histone H3, mitochondria, retrograde signaling, yeast genetics, reactive oxygen species, OXPHOS, nutrient signaling, histone degradation, PLOS Genetics, metabolic stress

The study exploited a deceptively simple but powerful model system, the budding yeast Saccharomyces cerevisiae. The researchers worked with 354 inbred yeast strains originally developed in a previous effort, a cohort that collectively carries roughly 12,000 single-nucleotide polymorphisms distributed across all yeast chromosomes and even the mitochondrial genome. Because the strains are inbred, their alleles segregate in an approximately 50:50 pattern, which gives the mapping approach clean statistical footing. Crucially, this kind of population has long been a workhorse for classical quantitative trait loci studies, but the Montreal team asked a question that had rarely been posed at this scale: rather than measuring visible traits or mRNA levels, could they measure the strength of protein–protein interactions themselves as quantitative traits, and then trace those measurements back to specific DNA variants?

To answer that question, the group deployed a protein-fragment complementation assay built on murine dihydrofolate reductase, or DHFR. The strategy works like a molecular switch. Each of two interacting partner proteins is fused to a complementary fragment of the DHFR enzyme. When the two proteins come together in the living cell, the fragments reconstitute a functional enzyme that confers resistance to the drug methotrexate. Growth under drug pressure therefore becomes a quantitative, high-throughput readout of interaction strength: the more strongly two proteins associate, the better the cells survive. The researchers engineered 61 such reporter pairs, tagging the relevant genes directly in the chromosomes of every strain using a streamlined CRISPR/Cas9 and homologous recombination workflow, and gave each strain a unique DNA barcode so that all 354 genomes could be pooled and sequenced together in a single competitive growth assay.

The results, presented across a series of Manhattan plots and quantitative maps, revealed a rich landscape the authors call the genetic architecture of protein–protein interactions, summarized in a new class of loci they named piQTLs, protein-interaction quantitative trait loci. Across 61 reporter pairs and five growth conditions, the team identified roughly 1,180 lead variants, about four per reporter pair per condition, corresponding to 354 unique SNPs spread over 282 distinct gene loci. The single most striking pattern concerned the split between cis- and trans-acting effects. Variants acting in cis, meaning they sit near the genes encoding the interacting pair itself, were rare. Variants acting in trans, located anywhere else in the genome and often on entirely different chromosomes, dominated the landscape and carried noticeably stronger per-variant effect sizes. In this respect, the regulation of protein interactions echoes a theme well established for gene expression, where trans effects are numerous and diffuse, but the interaction layer adds its own architectural twist.

That twist emerged when the researchers looked at where trans-piQTLs fall in the yeast protein interaction network. Consistent with the small-world architecture that characterizes protein networks, variants influencing a given reporter interaction tended to map to genes encoding proteins that sit close to that reporter pair in the network, even when the variants were far away in genomic space. The team formalized this observation through large-scale simulations, randomly drawing comparable sets of genes 10,000 times and asking how often they would fall as near to a reporter pair as the real piQTLs did. The answer was clear: the observed proximity was not a product of chance. This network-proximity principle is more than a statistical curiosity. It suggests that the web of interactions inside a cell channels the downstream effects of genetic variation, meaning that perturbations propagate along local neighborhoods of the interactome rather than scattering randomly, a property that could be exploited to prioritize candidate causal genes in human disease studies.

Perhaps the most provocative findings came from the poorly annotated corners of the yeast genome. The researchers identified and experimentally validated piQTLs in noncoding RNAs, including the Xrn1-sensitive antisense transcripts known as XUTs, as well as in 3′ untranslated regions, and these regulatory variants carried effect sizes comparable to those of variants landing squarely inside protein-coding sequences. In other words, DNA that does not code for protein can still measurably tune how two proteins grip each other in vivo. This finding expands the functional repertoire of noncoding variation and hints that some of the so-called missing heritability of complex human traits, the gap between known genetic associations and explained disease risk, may hide not only in unannotated regulatory DNA but in its consequences for the physical wiring of the proteome.

The study also delivered an instructive comparison with two other molecular QTL disciplines, expression QTLs that track mRNA abundance and protein abundance QTLs that track protein levels. When the team overlapped their piQTLs with results from highly powered yeast linkage studies, including an eQTL analysis of 942 diverse isolates and a pQTL analysis of 1,086 near telomere-to-telomere genomes, a telling asymmetry appeared: piQTLs overlapped more with pQTLs than with eQTLs, even after rigorous size-matched permutation testing. The interpretation is that protein interactions sit downstream of transcription and closer to the proteome-level machinery of the cell, capturing post-transcriptional regulation, protein abundance effects and molecular assembly processes that RNA measurements simply cannot see. Some variants alter how much of a protein is made; others change what that protein does once made, and the interactome assay registers both.

The practical payoff of the approach became visible when the researchers grew their pooled strains under drug treatment. In experiments with methotrexate, fluconazole, 5-fluorocytosine, metformin and trifluoperazine, drug-specific piQTLs emerged that traced the mechanism of action of each compound through the interaction network. Fluconazole, an antifungal that targets the Erg11 enzyme of the ergosterol pathway, produced piQTLs concentrated in genes linked to that pathway, including variants inside the Erg11 coding sequence itself. Metformin, the widely used diabetes drug, revealed interaction changes in mitochondrial and metabolic proteins that align with known aspects of its biology. This capacity to read a drug’s fingerprint directly off the interactome suggests that piQTL mapping could become a genuine screening tool, one that identifies variants modulating drug response and flags off-target mechanisms that conventional growth assays might miss entirely.

All of the raw sequencing data, computational code and mapping results have been released openly, with raw reads deposited in the Gene Expression Omnibus, analysis pipelines on GitHub, and an interactive web server that lets any visitor browse the Manhattan plots, quantile–quantile diagnostics and a genome browser annotated with noncoding RNA features. The authors acknowledge clear limitations, including the modest number of reporter interactions surveyed relative to the thousands of interactions known in yeast and the statistical power constraints of a 354-strain cohort, which can only detect effect sizes of roughly 0.06 or larger. Yet the conceptual advance is hard to overstate. By demonstrating that the strength of protein–protein interactions behaves as an ordinary quantitative trait that can be mapped across a genome, the study opens a third major molecular dimension for genetics, beyond transcript and protein abundance, and points toward a future in which the interpretive power of human genome-wide association studies is amplified by the connective tissue of the cell, the interaction networks where biology actually happens.

Subject of Research: Mapping how natural genetic variation alters in vivo protein–protein interaction strength in budding yeast.

Article Title: Genetic landscape of an in vivo protein interactome

Article References: Genetic landscape of an in vivo protein interactome. (n.d.). https://doi.org/10.1038/s41588-026-02747-z

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02747-z

Keywords: protein–protein interactions, piQTL, yeast genetics, quantitative trait loci, noncoding RNAs, GWAS, missing heritability, proteome, CRISPR, drug mechanisms, interaction networks, functional genomics